Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.41 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.37 |
| ▸ | MMP1 | P03956 | 1/20 | 0.37 |
| ▸ | MMP2 | P08253 | 1/20 | 0.37 |
| ▸ | MMP9 | P14780 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 2/20 | 0.36 |
| ▸ | F10 | P00742 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | GRM5 | P41594 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23901944 | 0.85 | TOP2A (0.51) | PARP10HRH3MMP1MMP2MMP9 | |
| SCHEMBL23902286 | 0.84 | MMP2 (0.41) | PARP10HRH3MMP1MMP2MMP9 | |
| SCHEMBL23901806 | 0.84 | FFAR4 (0.40) | HRH3F10 | |
| SCHEMBL23902202 | 0.82 | NPC1 (0.41) | HRH3NPC1RAB9A | |
| SCHEMBL23901853 | 0.81 | PTAFR (0.41) | HRH3F10 | |
| Hydrochloric Acid SCHEMBL23880741 | 0.80 | PTAFR (0.40) | HRH3F10 | |
| SCHEMBL23880701 | 0.78 | PARP10 (0.42) | PARP10HRH3MMP1MMP2MMP9 | |
| SCHEMBL23901790 | 0.75 | NPC1 (0.42) | NPC1RAB9A | |
| SCHEMBL8286902 | 0.75 | PTAFR (0.46) | F10 | |
| SCHEMBL34433936 | 0.74 | HDAC8 (0.43) | PARP10MMP1MMP2MMP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210309641-A1 | AMIDINES AND AMIDINE ANALOGS FOR THE TREATMENT OF BACTERIAL INFECTIONS AND POTENTIATION ANTIBIOTICS | GEORGIA STATE UNIVERSITY RESEARCH FOUNDATION, INC. (US) | 2021-10-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210309641-A1 | AMIDINES AND AMIDINE ANALOGS FOR THE TREATMENT OF BACTERIAL INFECTIONS AND POTENTIATION ANTIBIOTICS | PAM, AMPD1, AMPD3 | PARP10 1888/4885HRH3 178/4885MMP1 3804/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.